Frontage Announces Expansion of Business in Canada with New Leadership
Frontage Holdings Corporation (OTC:FTHCY) has announced the appointment of Dr. Abdul Mutlib as President of Frontage Laboratories, Canada, marking a strategic expansion of its services in the Canadian market. Dr. Mutlib, who will continue his role as Chief Scientific & Strategy Officer, will oversee operations in Toronto and Vancouver, reporting to Co-CEO Dr. Wentao Zhang.
With over 35 years of R&D experience in pharmaceutical and CRO sectors, Dr. Mutlib will focus on establishing Frontage as a key partner for Canada's growing biotech industry. The appointment aligns with Frontage's strategy to enhance its position as a leading global pharmaceutical Contract Research Organization (CRO).
Frontage Holdings Corporation (OTC:FTHCY) ha annunciato la nomina del Dott. Abdul Mutlib a Presidente di Frontage Laboratories, Canada, segnando un'espansione strategica dei suoi servizi nel mercato canadese. Il Dott. Mutlib, che manterrà il suo ruolo di Chief Scientific & Strategy Officer, supervisionerà le operazioni di Toronto e Vancouver, riportando direttamente al Co-CEO Dott. Wentao Zhang.
Con oltre 35 anni di esperienza in R&D nei settori farmaceutico e CRO, il Dott. Mutlib si concentrerà nel consolidare Frontage come partner chiave per l'industria biotecnologica canadese in crescita. Questa nomina è in linea con la strategia di Frontage di rafforzare la propria posizione come una delle principali Contract Research Organization (CRO) farmaceutiche a livello globale.
Frontage Holdings Corporation (OTC:FTHCY) ha anunciado el nombramiento del Dr. Abdul Mutlib como Presidente de Frontage Laboratories, Canadá, marcando una expansión estratégica de sus servicios en el mercado canadiense. El Dr. Mutlib, quien continuará en su rol de Chief Scientific & Strategy Officer, supervisará las operaciones en Toronto y Vancouver, reportando al Co-CEO Dr. Wentao Zhang.
Con más de 35 años de experiencia en I+D en los sectores farmacéutico y CRO, el Dr. Mutlib se enfocará en posicionar a Frontage como un socio clave para la creciente industria biotecnológica de Canadá. El nombramiento está alineado con la estrategia de Frontage para fortalecer su posición como una organización líder global de investigación por contrato farmacéutica (CRO).
Frontage Holdings Corporation (OTC:FTHCY)는 Dr. Abdul Mutlib를 Frontage Laboratories 캐나다 지사의 사장으로 임명했다고 발표하며, 캐나다 시장에서 서비스의 전략적 확장을 알렸습니다. Mutlib 박사는 Chief Scientific & Strategy Officer 역할을 계속 수행하면서 토론토와 밴쿠버의 운영을 총괄하며 공동 CEO인 Dr. Wentao Zhang에게 보고할 예정입니다.
제약 및 CRO 분야에서 35년 이상의 연구개발 경험을 가진 Mutlib 박사는 캐나다의 성장하는 바이오텍 산업에서 Frontage를 핵심 파트너로 자리매김하는 데 집중할 것입니다. 이번 임명은 Frontage가 글로벌 선도 제약 계약 연구기관(CRO)으로서의 입지를 강화하려는 전략과 일치합니다.
Frontage Holdings Corporation (OTC:FTHCY) a annoncé la nomination du Dr Abdul Mutlib en tant que président de Frontage Laboratories Canada, marquant une expansion stratégique de ses services sur le marché canadien. Le Dr Mutlib, qui conservera son rôle de Chief Scientific & Strategy Officer, supervisera les opérations à Toronto et Vancouver, sous la direction du co-CEO Dr Wentao Zhang.
Fort de plus de 35 ans d’expérience en R&D dans les secteurs pharmaceutique et CRO, le Dr Mutlib se concentrera sur l’établissement de Frontage comme partenaire clé de l’industrie biotechnologique canadienne en pleine croissance. Cette nomination s’inscrit dans la stratégie de Frontage visant à renforcer sa position de leader mondial des organisations de recherche sous contrat (CRO) pharmaceutiques.
Frontage Holdings Corporation (OTC:FTHCY) hat die Ernennung von Dr. Abdul Mutlib zum Präsidenten von Frontage Laboratories Kanada bekannt gegeben, was eine strategische Erweiterung der Dienstleistungen auf dem kanadischen Markt markiert. Dr. Mutlib, der weiterhin seine Rolle als Chief Scientific & Strategy Officer ausüben wird, übernimmt die Leitung der Standorte in Toronto und Vancouver und berichtet an den Co-CEO Dr. Wentao Zhang.
Mit über 35 Jahren Erfahrung in Forschung und Entwicklung in der Pharma- und CRO-Branche wird Dr. Mutlib sich darauf konzentrieren, Frontage als wichtigen Partner für die wachsende Biotech-Industrie Kanadas zu etablieren. Die Ernennung entspricht der Strategie von Frontage, seine Position als führende globale Contract Research Organization (CRO) im Pharmabereich zu stärken.
- Expansion into Canadian market with operations in Toronto and Vancouver
- Appointment of experienced leader with 35+ years of R&D expertise
- Strategic positioning to serve growing Canadian biotech industry
- None.
Dr. Mutlib brings more than 35 years of R&D experience in large pharmaceutical and CRO and will play a key role in establishing Frontage as a key partner and service provider to the rapidly growing biotech industry across
Dr. Zhang commented, "Abdul's leadership and experience has been vital to Frontage's growth over the last several years. His vision and strong leadership qualities will drive our success and expansion in
Dr. Mutlib expressed, "I'm deeply honored by this opportunity. I have full confidence in our Canadian team, and together, we aim to expand our services and significantly grow the business in the coming years. I'm excited to collaborate with Canadian authorities and establish Frontage as a leading provider of comprehensive, high-quality R&D services, supporting
About Frontage (www.frontagelab.com)
Frontage Holdings Corp (1521.HK), together with its wholly owned subsidiaries, including Frontage Laboratories, Inc., is a global Contract Research Organization (CRO) that provides integrated, science-driven, product development services from drug discovery to late-phase clinical process to enable biopharmaceutical companies to achieve their development goals. Comprehensive services include drug metabolism and pharmacokinetics, analytical testing and formulation development, preclinical and clinical trial material manufacturing, bioanalysis, preclinical safety and toxicology assessment, and early-phase clinical studies. Frontage has enabled many biotechnology companies and leading pharmaceutical companies of varying sizes to advance a myriad of new molecules through development and to successfully file global regulatory submissions. For more details visit www.frontagelab.com.
Media Contact:
Xiaoyun Niu
xniu@frontagelab.com
(610) 232-0100
View original content to download multimedia:https://www.prnewswire.com/news-releases/frontage-announces-expansion-of-business-in-canada-with-new-leadership-302494686.html
SOURCE Frontage Laboratories, Inc.
FAQ
Who is the new President of Frontage Laboratories Canada?
What are Frontage's expansion plans in Canada?
Who will Dr. Abdul Mutlib report to at Frontage Holdings?
What experience does Dr. Mutlib bring to Frontage Laboratories Canada?
